Download PDF
Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-2268-4129
Article

MiRNA Signatures Related to Invasiveness and Recurrence in Patients With Non-Functioning Pituitary Neuroendocrine Tumors

Emiliya Nikolova
1   Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
,
Anelia Nankova
2   Department of Endocrinology, Medical University-Sofia, USHATE “Acad. Ivan Penchev”, Sofia, Bulgaria
,
Silvia Kalenderova
1   Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
,
Bilyana Georgieva
1   Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
,
Asen Hadzhiyanev
3   Department of Neurosurgery, Medical University-Sofia, University Hospital “St. Ivan Rilski” Sofia, Bulgaria
,
Stoyan Bichev
4   National Genetic Laboratory, Medical University- Sofia, UHOG “Maichin dom”, Sofia, Bulgaria
,
Alexey Savov
4   National Genetic Laboratory, Medical University- Sofia, UHOG “Maichin dom”, Sofia, Bulgaria
,
Albena Todorova
1   Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
5   Genetic and Medico-diagnostic Laboratory “Genica”, Sofia, Bulgaria
,
Vanyo Mitev
1   Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
,
Atanaska Elenkova 
2   Department of Endocrinology, Medical University-Sofia, USHATE “Acad. Ivan Penchev”, Sofia, Bulgaria
› Author Affiliations Funding Information Medical University Sofia — http://dx.doi.org/10.13039/100009086; D-117/24.06.2020
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose: This preliminary study aimed to analyze and identify differentially expressed miRNAs in Bulgarian patients with non-functioning pituitary neuroendocrine tumors (NFPitNET). The relationship between deregulated miRNAs and tumor invasiveness, recurrence, and size was determined.

Methods: Twenty patients with NFPitNET were selected and fresh pituitary tumor tissues were collected. RNA containing miRNAs were isolated using miRNAeasy mini kit and analyzed by quantitative real-time polymerase chain reaction (PCR) using LNA miRNA Cancer-Focus PCR Panel (Qiagen).

Results: Three miRNAs (miR-210-3p, miR-149-3p, and miR-29b-3p) were deregulated in invasive compared to non-invasive NFPitNETs. Differential expression of four-miRNA signatures – miRNA-17, miR-19, miR-106a, and miR-20, correlated with patient recurrence.

Conclusion: This prospective pilot study selected a unique miRNA expression profile, that correlates with invasiveness and recurrence in non-functioning pituitary neuroendocrine tumors. Moreover, some of the selected miRNAs are reported for the first time in patients with this disease, shedding light on the molecular mechanisms involved in pituitary pathogenesis. The identified miRNAs demonstrate potential as biomarkers, deserving further investigation in a larger cohort to validate their clinical applicability.

Keywords

miRNA - non-functioning pituitary neuroendocrine tumors - invasion - recurrence


Publication History

Received: 27 July 2023
Received: 29 January 2024

Accepted: 06 February 2024

Accepted Manuscript online:
14 February 2024

Article published online:
15 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas: A systematic review. Cancer 2004; 101: 613-619
    CrossrefPubMedGoogle Scholar
  • 2 Chanson P, Raverot G, Castinetti F. et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76: 239-247
    CrossrefPubMedGoogle Scholar
  • 3 Raverot G, Burman P, McCormack A. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018; 178: G1-G24
    CrossrefPubMedGoogle Scholar
  • 4 Dekkers OM, Pereira AM, Roelfsema F. et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91: 1796-1801
    CrossrefPubMedGoogle Scholar
  • 5 Ragel BT, Couldwell WT. Pituitary carcinoma: A review of the literature. Neurosurg Focus 2004; 16: E7
    CrossrefPubMedGoogle Scholar
  • 6 Ezzat S, Asa SL. Mechanisms of disease: The pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab 2006; 2: 220-230
    CrossrefPubMedGoogle Scholar
  • 7 Wei Z, Zhou C, Liu M. et al. MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. Pituitary 2015; 18: 710-721
    CrossrefPubMedGoogle Scholar
  • 8 Bartel DP. Metazoan MicroRNAs. Cell 2018; 173: 20-51
    CrossrefPubMedGoogle Scholar
  • 9 Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: Tools for cancer diagnostics. Gut 2009; 58: 1546-1554
    CrossrefPubMedGoogle Scholar
  • 10 Zhang B, Pan X, Cobb GP. et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12
    CrossrefPubMedGoogle Scholar
  • 11 Ciafrè SA, Galardi S, Mangiola A. et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334: 1351-1358
    CrossrefPubMedGoogle Scholar
  • 12 Gadelha M, Kasuki J, Dénes J. et al. MicroRNAs: Suggested role in pituitary adenoma pathogenesis. J Endocrinol Invest 2013; 36: 889-895
    CrossrefPubMedGoogle Scholar
  • 13 Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7: 257-266
    CrossrefPubMedGoogle Scholar
  • 14 Di Ieva A, Butz H, Niamah M. et al. MicroRNAs as biomarkers in pituitary tumors. Neurosurgery 2014; 75: 181-188
    CrossrefPubMedGoogle Scholar
  • 15 Butz H, Likó I, Czirják S. et al. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas. Pituitary 2011; 14: 112-124
    CrossrefPubMedGoogle Scholar
  • 16 Wu S, Gu Y, Huang Y. et al. Novel biomarkers for non-functioning invasive pituitary adenomas were identified by using analysis of microRNAs expression profile. Biochem Genet 2017; 55: 253-267
    CrossrefPubMedGoogle Scholar
  • 17 Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: A population based study in Malta. Pituitary 2013; 16: 545-553
    CrossrefPubMedGoogle Scholar
  • 18 Yoshino H, Yonemori M, Miyamoto K. et al. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget 2017; 8: 20881-20894
    CrossrefPubMedGoogle Scholar
  • 19 Vicchio TM, Aliquò F, Ruggeri RM. et al. MicroRNAs expression in pituitary tumors: Differences related to functional status, pathological features, and clinical behavior. J Endocrinol Invest 2020; 43: 947-958
    CrossrefPubMedGoogle Scholar
  • 20 Zhao P, Cheng J, Li B. et al. Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas. Cell Biol Toxicol 2021; 37: 633-651
    CrossrefPubMedGoogle Scholar
  • 21 Yan B, Guo Q, Fu FJ. et al. The role of miR-29b in cancer: Regulation, function, and signaling. Onco Targets Ther 2015; 8: 539-548
    PubMedGoogle Scholar
  • 22 Xia J, Li S, Ma D. et al. MicroRNA-29-3p regulates the β-catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells. Mol Med Rep 2021; 23: 1-9
    CrossrefPubMedGoogle Scholar
  • 23 García-Martínez A, López-Muñoz B, Fajardo C. et al. Increased E2F1 mRNA and miR-17-5p expression is correlated to invasiveness and proliferation of pituitary neuroendocrine tumours. Diagnostics 2020; 10: 1-13
    CrossrefPubMedGoogle Scholar
  • 24 Ma Q, Peng Z, Wang L. et al. MiR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression. Int J Oncol 2016; 49: 2589-2599
    CrossrefPubMedGoogle Scholar
  • 25 Wang W, Liu L, Tian Y. miR-19-3p targets PTEN to regulate cervical cancer cell proliferation, invasion, and autophagy. Genet Res (Camb) 2023; 2023: 4784500
    CrossrefPubMedGoogle Scholar
  • 26 Lu WD, Zuo Y, Xu Z. et al. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. World J Gastroenterol 2015; 21: 4564-4573
    CrossrefPubMedGoogle Scholar
  • 27 Niu Y, Zhou H, Liu Y. et al. MiR-16 regulates proliferation and apoptosis of pituitary adenoma cells by inhibiting HMGA2. Oncol Lett 2019; 17: 2491-2497
    PubMedGoogle Scholar
  • 28 Cabana-Domínguez J, Arenas C, Cormand B. et al. MiR-9, miR-153 and miR-124 are down-regulated by acute exposure to cocaine in a dopaminergic cell model and may contribute to cocaine dependence. Transl Psychiatry 2018; 8: 173
    CrossrefPubMedGoogle Scholar
  • 29 Gangisetty O, Jabbar S, Wynne O. et al. MicroRNA-9 regulates fetal alcohol-induced changes in D2 receptor to promote prolactin production. J Endocrinol 2017; 235: 1-14
    CrossrefPubMedGoogle Scholar
  • 30 He Z, Chen L, Wang Q. et al. MicroRNA-186 targets SKP2 to induce p27Kip1-mediated pituitary tumor cell cycle deregulation and modulate cell proliferation. Korean J Physiol Pharmacol 2019; 23: 171-179
    CrossrefPubMedGoogle Scholar
  • 31 Németh K, Darvasi O, Likó I. et al. Comprehensive analysis of circulating miRNAs in the plasma of patients with pituitary adenomas. J Clin Endocrinol Metab 2019; 104: 4151-1468
    CrossrefPubMedGoogle Scholar
  • 32 Lu B, Liu GL, Yu F. et al. MicroRNA-16/VEGFR2/p38/NF-KB signaling pathway regulates cell growth of human pituitary neoplasms. Oncol Rep 2018; 39: 1235-1244
    PubMedGoogle Scholar
  • 33 Belaya Z, Khandaeva P, Nonn L. et al. Circulating plasma microRNA to differentiate Cushing’s disease from ectopic ACTH syndrome. Front Endocrinol (Lausanne) 2020; 11: 1-8
    CrossrefPubMedGoogle Scholar
  • 34 Zhao S, Li J, Feng J. et al. Identification of serum miRNA-423-5p expression signature in somatotroph adenomas. Int J Endocrinol 2019; 2019
    PubMedGoogle Scholar
  • 35 Licursi V, Conte F, Fiscon G. et al. MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinformatics 2019; 20: 545
    CrossrefPubMedGoogle Scholar
  • 36 Wang Y, Cheng T, Lu M. et al. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas. EPMA J 2019; 10: 395-414
    CrossrefPubMedGoogle Scholar
  • 37 Kowarik M, Onofri C, Colaco T. et al. Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells. Exp Clin Endocrinol Diabetes 2010; 118: 113-120 DOI: 10.1055/s-0029-1202832.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Yao X, Liu Q, Zhao S. et al. Expression and clinical significance of MDM2 in non-functioning PitNETs. Medicina (Kaunas) 2023; 59: 373
    CrossrefPubMedGoogle Scholar
  • 39 Yao X, Gao H, Li C. et al. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. J Neuroonco 2017; 132: 199-206
    CrossrefPubMedGoogle Scholar
  • 40 Cohen JI. Herpesviruses in the activated phosphatidylinositol-3-kinase-δ syndrome. Front Immunol 2018; 9: 237
    CrossrefPubMedGoogle Scholar